Skip to main content

Table 1 Comparison of the main demographic and clinical characteristics of study population

From: Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts

Variable

All episodes, N = 317 (%)

Non-septic shock, N = 218 (%)

Septic shock, N = 99 (%)

p value

Demographics

 Sex, male

184 (58.0)

141 (64.7)

43 (43.4)

0.17

 Mean age (± SD), years

65.4 ± 17.0

65.2 ± 18.6

66.9 ± 15.2

0.77

 Age ≥ 50 years

275 (86.4)

183 (83.9)

92 (92.9)

0.03

 Median hospital stay until Candida BSI (IQR), days

16 (7–31)

17 (6–32)

14 (8–28)

0.18

Hospital ward stay at the time of candidemia onset

 General ward

254 (80.1)

192 (88.1)

62 (62.6)

0.001

 Intensive care unit

63 (19.9)

26 (11.9)

37 (37.4)

Charlson comorbidity index

3.4 ± 2.7

3.4 ± 2.6

3.3 ± 2.8

0.71

Underlying condition

 Solid tumor

114 (35.9)

77 (35.3)

37 (37.4)

0.80

 Cardiovascular disease

102 (32.2)

69 (31.7)

33 (33.3)

0.79

 Diabetes mellitus

90 (28.4)

57 (26.1)

33 (33.3)

0.22

 Chronic Lung disease

51 (16.1)

35 (16.1)

16 (16.2)

1

 Chronic kidney failure

50 (15.8)

32 (14.7)

18 (18.2)

0.50

 Chronic liver disease

41 (12.9)

27 (12.4)

14 (14.1)

0.74

 Solid organ transplantation

27 (8.5)

19 (8.7)

8 (8.1)

1

 Hematological malignancy

20 (6.3)

16 (7.3)

4 (4.0)

0.32

 Hematopoietic stem cell transplantation

9 (2.8)

8 (3.7)

1 (1.0)

0.28

Risk factors for candidemia

 Previous antibiotic therapy

297 (93.6)

202 (92.7)

95 (96.0)

0.32

 Central venous catheter

225 (71.0)

150 (68.8)

75 (75.8)

0.23

 TPN during candidemia

158 (49.8)

101 (46.3)

57 (57.6)

0.07

 Previous corticosteroid therapy

72 (22.7)

51 (23.4)

21 (22.1)

0.77

 Abdominal surgery

85 (26.8)

52 (23.9)

33 (33.3)

0.10

 Immunosuppressive therapy

47 (14.8)

36 (16.5)

11 (11.1)

0.23

 Neutropenia

10 (3.2)

9 (4.1)

1 (1.0)

0.18

Previous antifungal treatment

49 (15.4)

37 (17.0)

12 (12.1)

0.32

Source of infection

 Central venous catheter

141 (44.5)

101 (46.3)

40 (40.4)

0.33

 Primary

98 (30.9)

73 (33.5)

25 (25.3)

0.15

 Abdomen

39 (12.3)

19 (8.7)

20 (20.2)

0.006

 Urinary tract

23 (7.3)

18 (8.3)

5 (5.1)

0.36

 Infective endocarditis

3 (0.9)

1 (0.5)

2 (2.0)

0.23

 Other

13 (4.1)

6 (2.8)

7 (7.1)

0.12

Candida species

C. albicans

134 (42.3)

91 (41.7)

43 (43.4)

0.80

C. glabrata

58 (18.3)

38 (17.4)

20 (20.2)

0.63

C. parapsilosis

55 (17.4)

40 (18.3)

15 (15.2)

0.52

C. tropicalis

29 (9.1)

22 (10.1)

7 (7.1)

0.52

C. krusei

6 (1.9)

4 (1.8)

2 (2.0)

1

C. lusitaniae

4 (1.3)

2 (0.9)

2 (2.0)

0.59

C. auris

27 (8.5)

18 (8.3)

9 (9.1)

0.86

 Other

13 (4.1)

11 (5.0)

2 (2.0)

0.35

Resistant strains

 Fluconazole

45 (14.1)

29 (13.3)

16 (16.2)

0.73

 Echinocandins

3 (0.9)

2 (0.9)

1 (1.0)

1

  1. BSI bloodstream infection, IQR interquartile range, SD standard deviation, TPN total parenteral nutrition